New aspects of the therapy of urge incontinence with trospium chloride;Neue aspekte zur therapie der harndranginkontinenz mit trospiumchlorid

European Journal of Geriatrics

Volumn 3, Issue 1, 2001, Pages 41-45

  Wiedemann, A ^a   Fusgen I ^a   Hauri, D ^a  

^a Marienhospital Gelsenkirchen GmbH   (Germany)

Author keywords

Anticholinergic agents; Overactive bladder; Trospium chloride; Urinary incontinence

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; FLUOXETINE; ITRACONAZOLE; KETOCONAZOLE; OXYBUTYNIN; SPASMOLYTIC AGENT; TOLTERODINE; TROSPIUM CHLORIDE; WARFARIN;

ARTICLE; COST CONTROL; DETRUSOR MUSCLE; ELDERLY CARE; HUMAN; MUSCLE CONTRACTILITY; QUALITY OF LIFE; URGE INCONTINENCE;

EID: 0035119851     PISSN: 14391147     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Trospium chloride (Spasmo-lyt() in patients with motor urge syndrome (detrusor instability) a double-blind, randomized, multicentre, placebo-controlled study
2. Inhibitory effects of trospium chloride on cytochrome P450 in human liver microsomes
3. Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance
4. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity
5. Efficacy of trospium chloride in patients with detrusor instability: A placebo-controlled, randomized, double-blind multicentre clinical trial
6. Tolterodin-warfarin drug interaction
7. Structural basis of geriatric voiding dysfunction. III: Detrusor overactivity
8. Trospium chloride: An effective option for medical treatment of bladder overactivity
9. Alltags- und Verkehrssicherheit unter Inkontinenz-Medikation: Neue Untersuchungen zum Sicherheitspotential urologischer Anticholinergika
10. Neue Aspekte in der Therapie der Harndranginkontinenz: Lebensqualität, Trinkverhalten und Versorgungssituation
11. Tolerability and efficacy of trospium chloride in a long-term treatment (52 weeks) in patients with urge-syndrome: A double-blind, controlled, multicentre clinical trial
12. Efficacy and Tolerability of Trospium chloride and Tolterodine in 234 patients with urge-syndrome: A double-blind, placebo-controlled, multicentre clinical trial
13. Trospiumchloride 40 mg - A placebo-controlled, randomised, double-blind clinical trial, on the efficacy and tolerability for 3 weeks in patients with urge-syndrome
14. Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of active metabolite
15. Trospiumchlorid (Spasmo-lyt() in der Allgemeinpraxis - Therapeutische Erfahrungen in der Behandlung der Reizblasensymptomatik und der Dranginkontinenz
16. Statements of the committees of the WHO consensus conference, August 20
17. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers
18. Medikamente bei Miktionsstörungen im Alter
19. Harninkontinenz versorgung in der Bundesrepublik Deutschland
20. Costs of urinary incontinence - Results of a questionnaire in 2160 patients